At the outset, G‐CSF utilization was reviewed in patients receiving chemotherapy for metastatic disease and it was deemed best to permit clinical discretion for use based on acceptable guidelines (e.g., age, comorbidities, myelotoxic risk of regimen among others) rather than prescribe this. Here, CSF3 is linked to metastatic neoplasm.